title: Effects of proton pump inhibitors on pediatric inflammatory esophagogastric polyps.
abstract: BACKGROUND
  The aim of this study was to investigate the effects of proton pump inhibitors on symptomatic inflammatory esophagogastric polyps (IEPs) in a pediatric cohort and to determine the optimal duration of treatment.
  
  
  METHODS
  The 11 patients with IEPs were managed with lansoprazole. Follow-up endoscopies were performed at 2 and 6 months after the start of medication. Medication was discontinued when the clinical symptoms completely resolved and the polyp size was reduced by more than 50% compared to the initial size.
  
  
  RESULTS
  The initial polyp size was 13.7 ± 3.3 mm. After 2 months of medication, the polyp size was reduced to 8.0 ± 5.8 mm. At 6 months, the polyp size was 4.7 ± 2.2 mm. The mean duration of medication was 4.8 ± 2.1 months. The duration of medication and the change in the polyp size appeared to have a linear correlation (p < 0.001). According to the formula used to calculate polyp size, the optimal duration of treatment was more than 7 months for complete resolution of the polyps.
  
  
  CONCLUSIONS
  Proton pump inhibitor was effective for the treatment of IEPs. About 5 months of lansoprazole was adequate to treat IEPs in children. The optimal duration for complete resolution of the polyp might be more than 7 months.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: Kyong Eun
authors.initials: KE
authors.lastname: Choi
authors.forename: Mi Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Ji Hyuk
authors.initials: JH
authors.lastname: Lee
authors.forename: Jong Seung
authors.initials: JS
authors.lastname: Lee
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Yon Ho
authors.initials: YH
authors.lastname: Choe
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004724:Endoscopy; D004935:Esophageal Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004943:Esophagogastric Junction / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D064747:Lansoprazole; D008297:Male; D011127:Polyps / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D013272:Stomach Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole